ZIPSOR Drug Patent Profile
✉ Email this page to a colleague
When do Zipsor patents expire, and when can generic versions of Zipsor launch?
Zipsor is a drug marketed by Assertio and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.
The generic ingredient in ZIPSOR is diclofenac potassium. There are forty-seven drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the diclofenac potassium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zipsor
A generic version of ZIPSOR was approved as diclofenac potassium by TEVA on August 6th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZIPSOR?
- What are the global sales for ZIPSOR?
- What is Average Wholesale Price for ZIPSOR?
Summary for ZIPSOR
US Patents: | 6 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 57 |
Clinical Trials: | 3 |
Patent Applications: | 4,575 |
Drug Prices: | Drug price information for ZIPSOR |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ZIPSOR |
What excipients (inactive ingredients) are in ZIPSOR? | ZIPSOR excipients list |
DailyMed Link: | ZIPSOR at DailyMed |
Recent Clinical Trials for ZIPSOR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Depomed | Phase 4 |
Hospira, now a wholly owned subsidiary of Pfizer | Phase 1 |
Hospira, Inc. | Phase 1 |
Pharmacology for ZIPSOR
Drug Class | Nonsteroidal Anti-inflammatory Drug |
Mechanism of Action | Cyclooxygenase Inhibitors |
Physiological Effect | Decreased Prostaglandin Production |
Paragraph IV (Patent) Challenges for ZIPSOR
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ZIPSOR | Capsules | diclofenac potassium | 25 mg | 022202 | 1 | 2012-11-14 |
US Patents and Regulatory Information for ZIPSOR
ZIPSOR is protected by six US patents and one FDA Regulatory Exclusivity.
Patents protecting ZIPSOR
Method of treating post-surgical acute pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
Method of treating post-surgical acute pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
Method of treating post-surgical acute pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
Method of treating post-surgical acute pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
Method of treating post-surgical acute pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
Method of treating post-surgical acute pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
FDA Regulatory Exclusivity protecting ZIPSOR
NEW PATIENT POPULATION
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZIPSOR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZIPSOR
See the table below for patents covering ZIPSOR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 1407887 | ⤷ Sign Up | |
Russian Federation | 2252019 | ПЕРОРАЛЬНЫЕ ЖИДКИЕ КОМПОЗИЦИИ (PERORAL LIQUID COMPOSITIONS) | ⤷ Sign Up |
Ukraine | 80085 | ORAL LIQUID COMPOSITIONS | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |